Valuation: DexCom, Inc.

Market Cap 31.33B 537B 27.15B 25.62B 23.24B 43.6B 3,003B 43.92B 306B 118B 1,523B 118B 115B 4,843B P/E 2026 *
33.3x
P/E 2027 * 28x
Enterprise Value 30.57B 524B 26.49B 25B 22.68B 42.54B 2,930B 42.85B 299B 115B 1,486B 115B 112B 4,726B EV / Sales 2026 *
5.85x
EV / Sales 2027 * 5.22x
Free-Float
91.27%
Yield 2026 *
-
Yield 2027 * -
1 day-0.57%
1 month-1.03%
3 months+23.14%
6 months+19.08%
Current year+26.05%
1 month 1,529
Extreme 1529
1,556.82
Current year 1,064.65
Extreme 1064.65
1,556.82
1 year 1,062.55
Extreme 1062.55
1,556.82
3 years 1,062.55
Extreme 1062.55
2,260
5 years 1,062.55
Extreme 1062.55
3,366.38
10 years 212.78
Extreme 212.775
3,366.38
Manager TitleAgeSince
Chief Executive Officer 47 01/01/2026
Director of Finance/CFO 46 19/03/2021
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Chairman 68 30/07/2018
Director/Board Member 67 20/11/2009
Director/Board Member 47 01/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%-.--% - - 31.33B
+1.03%-2.51%-21.67%+0.21% 176B
+2.78%+0.78%-0.34%+13.61% 116B
+1.32%+0.31%+11.77%+84.01% 61.36B
-1.15%-7.08%+5.83%+39.93% 49.42B
+2.05%+1.10%-2.51%-31.57% 48.44B
+1.57%-0.37%+11.43%-17.07% 31.33B
0.00%-6.62% - - 28.54B
+2.58%+4.99%+37.70%-10.88% 24.37B
+0.73%-6.97%-12.66%+4.70% 21.57B
Average +1.00%-4.92%+3.69%+10.37% 61.98B
Weighted average by Cap. +1.21%-4.84%-3.72%+12.32%

Financials

2026 *2027 *
Net sales 5.23B 89.6B 4.53B 4.28B 3.88B 7.28B 501B 7.33B 51.08B 19.68B 254B 19.64B 19.21B 808B 5.8B 99.35B 5.03B 4.74B 4.3B 8.07B 556B 8.13B 56.64B 21.83B 282B 21.78B 21.3B 897B
Net income 974M 16.69B 844M 797M 723M 1.36B 93.39B 1.37B 9.52B 3.67B 47.38B 3.66B 3.58B 151B 1.15B 19.68B 996M 940M 852M 1.6B 110B 1.61B 11.22B 4.32B 55.86B 4.32B 4.22B 178B
Net Debt -761M -13.04B -660M -622M -565M -1.06B -72.95B -1.07B -7.43B -2.86B -37.01B -2.86B -2.8B -118B -1.06B -18.18B -920M -868M -787M -1.48B -102B -1.49B -10.37B -3.99B -51.61B -3.99B -3.9B -164B
Logo DexCom, Inc.
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 71.5% of net sales.
Employees
11,050
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
83.03USD
Average target price
94.12USD
Spread / Average Target
+13.36%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!